202 related articles for article (PubMed ID: 18210116)
1. [Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small-cell hepatic carcinoma: case reports and review of the literature].
Balta Z; Sauerbruch T; Hirner A; Büttner R; Fischer HP
Pathologe; 2008 Feb; 29(1):53-60. PubMed ID: 18210116
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine small cell rectal cancer metastasizing to the liver: a unique treatment strategy, case report, and review of the literature.
Al-Jiffry BO; Al-Malki O
World J Surg Oncol; 2013 Jul; 11():153. PubMed ID: 23844568
[TBL] [Abstract][Full Text] [Related]
3. [Poorly-differentiated neuroendocrine carcinoma of ascending colon with liver metastases successfully treated with carboplatin and etoposide].
Akiyama S; Niitani T; Narasaka T; Ohto T; Gamoh M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1209-12. PubMed ID: 21772114
[TBL] [Abstract][Full Text] [Related]
4. [Neuroendocrine tumors: analysis of 252 cases].
Chi YH; Jiang WC; Du F; Sun YK; Song Y; Yang L; Zhou AP; Wang JW
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):67-70. PubMed ID: 23648305
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
6. Collision tumor of hepatocellular carcinoma and neuroendocrine carcinoma involving the liver: Case report and review of the literature.
Choi GH; Ann SY; Lee SI; Kim SB; Song IH
World J Gastroenterol; 2016 Nov; 22(41):9229-9234. PubMed ID: 27895410
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence.
Broaddus RR; Herzog CE; Hicks MJ
Arch Pathol Lab Med; 2003 Sep; 127(9):1200-3. PubMed ID: 12946222
[TBL] [Abstract][Full Text] [Related]
8. [Case of primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy].
Hasegawa H; Kuzushita N; Nakazuru S; Itoh M; Araki M; Yoshioka C; Suemura S; Ohta M; Yoshio T; Toyama T; Ikura Y; Mita E
Nihon Shokakibyo Gakkai Zasshi; 2010 Dec; 107(12):1956-62. PubMed ID: 21139365
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.
Moertel CG; Kvols LK; O'Connell MJ; Rubin J
Cancer; 1991 Jul; 68(2):227-32. PubMed ID: 1712661
[TBL] [Abstract][Full Text] [Related]
10. Hepatic primary neuroendocrine carcinoma: about a new case.
Derouich H; Haddad F; Moukhlissi M; Hliwa W; Bellabah A; Badre W
Pan Afr Med J; 2015; 20():254. PubMed ID: 26161177
[TBL] [Abstract][Full Text] [Related]
11. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis and treatment of primary hepatic neuroendocrine carcinoma].
Xu K; Chen Y; Chen M; Zhang W; Wang Y; Ji W; Wang H; Xin X; Feng J; Li Y; Yan L
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):451-5. PubMed ID: 26463150
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
[TBL] [Abstract][Full Text] [Related]
15. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
Gupta A; Duque M; Saif MW
JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic features of primary renal neuroendocrine carcinoma].
Wang XH; Lu X; He B; Jiang YX; Yu WJ; Wang H; Zhang W; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):851-856. PubMed ID: 30423609
[No Abstract] [Full Text] [Related]
17. Atypical carcinoid of the uterine cervix accompanying adenocarcinoma in situ.
Ling C; Shen Y
J Clin Pathol; 2018 Nov; 71(11):1030. PubMed ID: 30154130
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience.
Olsen IH; Langer SW; Jepsen I; Assens M; Federspiel B; Hasselby JP; Hansen CP; Kjaer A; Knigge U
Acta Oncol; 2012 Jan; 51(1):97-100. PubMed ID: 21615243
[TBL] [Abstract][Full Text] [Related]
19. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report.
Semrau S; Agaimy A; Pavel M; Lubgan D; Schmidt D; Cavallaro A; Golcher H; Grützmann R; Fietkau R
J Med Case Rep; 2019 Mar; 13(1):82. PubMed ID: 30902067
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and outcomes of primary hepatic neuroendocrine carcinomas.
Park CH; Chung JW; Jang SJ; Chung MJ; Bang S; Park SW; Song SY; Chung JB; Park JY
J Gastroenterol Hepatol; 2012 Aug; 27(8):1306-11. PubMed ID: 22414232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
